The Septic Shock Market Size is Anticipated to Increase During the Study Period 2019-2032 | Companies- Adrenomed AG, Vivacelle Bio, Inotrem, Atox Bio, AM-Pharma, and others

The Septic Shock market report provides current treatment practices, emerging drugs, Septic Shock market share of individual therapies, and current and forecasted Septic Shock market size from 2019 to 2032, segmented by seven major markets. The report also covers current Septic Shock treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Discover more about therapies set to grab major Septic Shock Market Share @ Septic Shock Market Size- https://www.delveinsight.com/sample-request/septic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Septic Shock Market Report
• According to the study by Annane et al. (2003), the percentage of females stayed in ICU due to septic shock was 36.7%
• The leading Septic Shock Companies include Adrenomed AG, Vivacelle Bio, Inotrem, Atox Bio, AM-Pharma, Eli Lilly and Company, La Jolla Pharmaceutical Company, Techpool Bio-Pharma Co., Ltd, AstraZeneca, Bayer, Biosyn, Brahms AG, and others.
• Promising Septic Shock Pipeline Therapies include sodium-selenite, Drotrecogin alfa (activated), meropenem, moxifloxacin, ulinastatin, Angiotensin II, hemoperfusion, saline, albumin, and others

Septic Shock Epidemiology Segmentation in the 7MM
• Total Septic Shock Incident Cases
• Septic Shock Gender-specific Incident Cases
• Septic Shock Treatable Cases

Download the report to understand which factors are driving Septic Shock Epidemiology Trends @ Septic Shock Epidemiological Insights- https://www.delveinsight.com/sample-request/septic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Septic Shock Overview
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis can be the clinical manifestation of infections acquired both in the community setting and in health care facilities.

Septic Shock Therapeutics Market
Overall, the global septic shock therapeutics market is further expected to increase by the major drivers such as rising population, technological advancements, and upcoming therapies in the forecast period [2023-2032]. Normalization of blood glucose improves outcome in critically ill patients, even those not known to be diabetic, because hyperglycemia impairs the immune response to infection. A continuous intravenous (IV) insulin infusion is titrated to maintain glucose between 110-180 mg/dL. This approach necessitates frequent (e.g. every 1-4 h) glucose measurement. Corticosteroid therapy may be beneficial in patients who remain hypotensive despite treatment with IV fluids, source control, antibiotics, and vasopressors. In severe cases of sepsis or septic shock, the large decrease in blood pressure and blood flow leads to death of body tissues and these may required to be removal by surgery.

To know more about Septic Shock Therapies options, visit @ Septic Shock Therapeutics Market- https://www.delveinsight.com/sample-request/septic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Septic Shock Treatment Landscape

• Adrenomed AG is developing Adrecizumab, a monoclonal antibody designed to act on the vasoprotective peptide, adrenomedullin, to re-establish and sustain vascular integrity. Adrenomedullin is a free-circulating peptide generated by vascular endothelial cells. In February 2020, the company released top-line AdrenOSS-2 Phase II results, showing that the study achieved its primary endpoint and in September 2020, the company presented positive results from Adrenomed's AdrenOSS-2 Phase II trial evaluating Adrecizumab (HAM8101) in Septic Shock presented during e-ISICEM.

• VBI-S is a being developed by Vivacelle Bio for the treatment of septic shock. It is a colloid non-blood volume expander that appears to be two to three times more effective than the standard treatment for hypovolemia and safer in animal studies. The clinical trial of VBI-S in patients in whom other fluids have failed to elevate their blood pressure is now in progress at multiple hospitals. This trial is supported by a 5.3 million dollar grant from the Naval Medical Research Center. The company is currently evaluating the drug in the Phase II clinical trial for the treatment of septic shock, and is recruiting candidates for clinical trial.

Septic Shock Emerging Drugs

• Adrecizumab: Adrenomed
Adrecizumab is a proprietary humanized monoclonal adrenomedullin (ADM) specific antibody. This targeted therapy inhibits excessive circulating sepsis-induced ADM, stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects. Currently, it is in Phase II stage of clinical trial evaluation to treat septic shock.

• Nangibotide: Inotrem
Nangibotide is a chemically synthesized peptide and a specific TREM-1 inhibitor. Among other features, nangibotide modulation restores a balanced inflammatory response (immunomodulation) and improves survival (shock reversal). Inotrem's lead product candidate, nangibotide (LR12), has been granted access to the EMA's PRIority MEdicines (PRIME) scheme. The Food and Drug Administration has granted Fast Track designation to nangibotide for the treatment of septic shock.

Septic Shock Emerging Therapy Assessment
Companies across the globe are diligently working toward the development of novel therapies with a considerable amount of success over the years. Key players, such as Adrenomed AG, Vivacelle Bio, Inotrem, etc., are developing therapies for the treatment of Septic Shock.

Learn more about the Septic Shock Pipeline Therapies in clinical trials @ Septic Shock SWOT Analysis, Unmet Needs, Reimbursement, and Patient Journey- https://www.delveinsight.com/sample-request/septic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Septic Shock Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Septic Shock Companies- Adrenomed AG, Vivacelle Bio, Inotrem, Atox Bio, AM-Pharma, Eli Lilly and Company, La Jolla Pharmaceutical Company, Techpool Bio-Pharma Co., Ltd, AstraZeneca, Bayer, Biosyn, Brahms AG, and others.
• Septic Shock Pipeline Therapies- sodium-selenite, Drotrecogin alfa (activated), meropenem, moxifloxacin, ulinastatin, Angiotensin II, hemoperfusion, saline, albumin, and others.
• Septic Shock Market Dynamics: Septic Shock Market Drivers and Barriers

Discover more about Septic Shock Drugs in development @ Septic Shock Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/septic-shock-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Septic Shock
3. Competitive Intelligence Analysis for Septic Shock
4. Septic Shock: Market Overview at a Glance
5. Septic Shock: Disease Background and Overview
6. Patient Journey
7. Septic Shock Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Septic Shock Unmet Needs
10. Key Endpoints of Septic Shock Treatment
11. Septic Shock Marketed Products
12. Septic Shock Emerging Therapies
13. Septic Shock: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Septic Shock
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.